

Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

SECTION 1. IDENTIFICATION

Product identifier : Temozolomide Formulation

Manufacturer or supplier's details

Company : MSD

Address : Avenue Comendador Antônio Loureiro Ramos,

nº 1500 - Distrito Industrial

Montes Claros - MG, Brazil 39404-620

Telephone : +55 (38) 3229 7000

Emergency telephone : +55 (38) 3201 5670

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Acute toxicity (Oral) : Category 2

Eye irritation : Category 2A

Germ cell mutagenicity : Category 2

Carcinogenicity : Category 2

Reproductive toxicity : Category 1B

Specific target organ toxicity - :

Category 1 (Bone marrow, thymus gland, Lymph nodes,

repeated exposure (Oral) spleen)

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :





Signal Word : Danger

Hazard Statements : H300 Fatal if swallowed.

H319 Causes serious eye irritation.

H341 Suspected of causing genetic defects.



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

H351 Suspected of causing cancer.

H360FD May damage fertility. May damage the unborn child. H372 Causes damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure

if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P301 + P310 + P330 IF SWALLOWED: Immediately call a

POISON CENTER/ doctor. Rinse mouth.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and

easy to do. Continue rinsing.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P337 + P313 If eye irritation persists: Get medical advice/ at-

tention.

Storage:

P405 Store locked up.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)	
Temozolomide	85622-93-1	Acute Tox. (Oral), 2 Muta., 2 Carc., 2 Repr., 1B STOT RE, (Oral)(Bone marrow, thymus gland, Lymph nodes, spleen), 1	>= 50 -< 70	
Stearic acid	57-11-4		>= 1 -< 5	
(+)-Tartaric acid	87-69-4	Acute Tox. (Oral), 5 Eye Dam., 1 Aquatic Acute, 3	>= 1 -< 2,5	

SECTION 4. FIRST AID MEASURES



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Call a physician or poison control center immediately.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

delayed

Fatal if swallowed.

Causes serious eye irritation.
Suspected of causing genetic defects.

Suspected of causing cancer.

May damage fertility. May damage the unborn child.
Causes damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Minimize dust generation and accumulation.



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

> Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides Flammable liquids Flammable solids Pyrophoric liquids Pyrophoric solids

Self-heating substances and mixtures

Substances and mixtures which in contact with water emit

flammable gases

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 μg/100 cm2	Internal
Stearic acid	57-11-4	TWA (Inhalable particulate matter)	10 mg/m³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH

Engineering measures : Use closed processing systems or containment technologies



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into

the workplace.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type
Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Color : off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : No data available

Evaporation rate : No data available



Temozolomide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 31.01.2024

 9.0
 28.09.2024
 25431-00024
 Date of first issue: 24.10.2014

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 1 g/cm³

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.



Temozolomide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 31.01.2024

 9.0
 28.09.2024
 25431-00024
 Date of first issue: 24.10.2014

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation Skin contact

Ingestion Eye contact

Acute toxicity

Fatal if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 33,92 mg/kg

Method: Calculation method

Components:

Temozolomide:

Acute oral toxicity : LD50 (Dog): 19 mg/kg

LD50 (Rat): 315 mg/kg

LD50 (Mouse): 205 mg/kg

Stearic acid:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 2 mg/l

Exposure time: 1 h
Test atmosphere: vapor

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

(+)-Tartaric acid:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 423

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Stearic acid:



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

Species : Rabbit

Method : Patch Test 24 Hrs.
Result : No skin irritation

(+)-Tartaric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Stearic acid:

Species : Rabbit

Result : No eye irritation

(+)-Tartaric acid:

Species : Bovine cornea

Method : OECD Test Guideline 437

Result : Irreversible effects on the eye

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Temozolomide:

Test Type : Maximization Test

Routes of exposure : Dermal
Species : Guinea pig
Result : negative

Stearic acid:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

(+)-Tartaric acid:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact Species : Mouse

Method : OECD Test Guideline 429



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

Result : negative

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:

Temozolomide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: Chromosome aberration test in vitro

Test system: Human lymphocytes

Result: positive

Germ cell mutagenicity -

Assessment

Positive results from in vitro mammalian mutagenicity assays,

chemical structure activity relationship to known germ cell

mutagens

Stearic acid:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

(+)-Tartaric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Result: negative

Remarks: Based on data from similar materials

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: positive

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

Carcinogenicity

Suspected of causing cancer.

Components:

Temozolomide:

Species : Rat
Application Route : Oral
Exposure time : 6 Months

: 4 mg/kg body weight

Result : positive

Target Organs : Mammary gland

Carcinogenicity - Assess-

ment

: Limited evidence of carcinogenicity in animal studies

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Temozolomide:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: LOAEL: 8,5 mg/kg body weight

Result: positive

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Embryo-fetal toxicity.: LOAEL: 13 mg/kg body weight Result: positive, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and

fertility, based on animal experiments., Clear evidence of

adverse effects on development, based on animal

experiments.

Stearic acid:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

II

(+)-Tartaric acid:

Effects on fetal development: Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Components:

Temozolomide:

Routes of exposure : Ingestion

Target Organs : Bone marrow, thymus gland, Lymph nodes, spleen

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Temozolomide:

Species : Rat, female
NOAEL : 4 mg/kg
LOAEL : 21 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Lymph nodes, thymus gland, Bone marrow, Reproductive

organs

Species : Rat, male
NOAEL : 8,5 mg/kg
LOAEL : 34 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Lymph nodes, thymus gland, Bone marrow, male reproductive

organs, Gastrointestinal tract

Species : Dog
NOAEL : 2,5 mg/kg
LOAEL : 6,3 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Bone marrow, spleen, male reproductive organs, Gastrointes-

tinal tract, thymus gland

Stearic acid:

Species : Rat



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

NOAEL : 1.000 mg/kg
Application Route : Ingestion
Exposure time : 42 Days

Method : OECD Test Guideline 422

Remarks : Based on data from similar materials

(+)-Tartaric acid:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Temozolomide:

Ingestion : Symptoms: Blood disorders, Nausea, Vomiting, Diarrhea,

anorexia, Fatigue, hair loss

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Temozolomide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 90

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 40

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Stearic acid:



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

Toxicity to fish : LL50 (Leuciscus idus (Golden orfe)): > 10.000 mg/l

Exposure time: 48 h Method: DIN 38412

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

NOELR (Pseudokirchneriella subcapitata (green algae)): > 10

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chron-

ic toxicity)

NOELR (Daphnia magna (Water flea)): > 0,5 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to microorganisms : EC10 (Pseudomonas putida): 883 mg/l

Exposure time: 18 h

(+)-Tartaric acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 93,313 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 51,404

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3,125

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 1.000 mg/l

Exposure time: 3 h



Temozolomide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 31.01.2024

 9.0
 28.09.2024
 25431-00024
 Date of first issue: 24.10.2014

Method: OECD Test Guideline 209

Persistence and degradability

Components:

Temozolomide:

Biodegradability : Result: rapidly degradable

Biodegradation: 83 % Exposure time: 35 d

Stability in water : Degradation half life (DT50): < 1 d

Stearic acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 71 % Exposure time: 28 d

Method: OECD Test Guideline 301B

(+)-Tartaric acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 85 % Exposure time: 28 d

Method: OECD Test Guideline 306

Bioaccumulative potential

Components:

Temozolomide:

Partition coefficient: n- : log Pow: 1,35

octanol/water

Stearic acid:

Partition coefficient: n-

: log Pow: 8,23

octanol/water

(+)-Tartaric acid:

Partition coefficient: n-

: log Pow: -1,91

octanol/water

Mobility in soil
No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste



Temozolomide Formulation

Version **Revision Date:** SDS Number: Date of last issue: 31.01.2024 28.09.2024 25431-00024 Date of first issue: 24.10.2014 9.0

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans -

(LINACH)

Not applicable

Brazil. List of chemicals controlled by the Federal

Police

Not applicable

The ingredients of this product are reported in the following inventories:

AICS not determined

DSL not determined

IECSC not determined

SECTION 16. OTHER INFORMATION

Revision Date 28.09.2024 Date format dd.mm.yyyy

Further information

Sources of key data used to

compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/



Temozolomide Formulation

Version Revision Date: SDS Number: Date of last issue: 31.01.2024 9.0 28.09.2024 25431-00024 Date of first issue: 24.10.2014

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization: ISHL - Industrial Safety and Health Law (Japan): ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8